Phase 1 Pomalidomide After CAR T-Cell Therapy for Relapsed or Refractory CD19+ B-Cell Leukemia or Lymphoma
Summary
The NIH National Library of Medicine registered Phase 1 clinical trial NCT07532525 to evaluate pomalidomide following CD19 CAR T-cell therapy for relapsed or refractory CD19+ B-cell leukemia or lymphoma. The single-arm trial will assess safety and preliminary effectiveness of the combination therapy in approximately 24 participants.
What changed
The NIH National Library of Medicine registered a new Phase 1 clinical trial (NCT07532525) investigating pomalidomide as sequential therapy following CD19 CAR T-cell treatment for relapsed or refractory CD19+ B-cell malignancies. The single-arm study will assess the combination regimen's safety profile and preliminary efficacy.
Clinical investigators, healthcare providers, and pharmaceutical companies involved in cellular therapy or hematologic malignancy research should note this trial registration for awareness of emerging combination strategies in the CAR T-cell treatment landscape.
Archived snapshot
Apr 17, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma
Phase 1 NCT07532525 Kind: PHASE1 Apr 16, 2026
Abstract
This phase I trial tests the safety and effectiveness of pomalidomide after CD19 chimeric antigen receptor T-cell (CD19CART) therapy for the treatment of patients with CD19+ B-cell leukemias or lymphomas that have come back after a period of improvement (relapsed) or do not respond to treatment (refractory). Chimeric antigen receptor (CAR) T-cell therapy is a type of treatment in which a patient's T-cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells and are then re-infused into the patient. Following CAR T-cell infusion, CAR T-cells must expand and persist in the blood stream in order to most effectively treat leukemia/lymphoma. Pomalidomide stops the growth of blood vessels, stimulates the immune system, and may kill cancer cells. Research has shown that drugs like pomalidomide can modify the immune system and increase the number or improve the function of CAR T-cells in the blood. Pomalidomide may enhance the treatment effects of CAR T-cell therapy in patients who have received CD19CART therapy for relapsed or refractory CD19+ B-cell leukemia or lymphoma.
Conditions: Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory B Acute Lymphoblastic Leukemia, Refractory B-Cell Non-Hodgkin Lymphoma
Interventions: Biospecimen Collection, Pomalidomide
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH/NLM.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.